Exact Sciences Achieves Milestone in Breast Cancer Genomics with 2 Million Patient Mark.

Exact Sciences has reached a milestone of 2 million patients using its Oncotype DX Breast Recurrence Score test worldwide. This test guides individualized breast cancer treatment and helps avoid unnecessary chemotherapy. The milestone reinforces Exact Sciences' role in genomic diagnostics for breast cancer care and could influence its scale in genomic diagnostics. Investors will likely focus on broader adoption of the Oncotype DX test and similar assays.